Acupuncture added to mesalazine for mild-to-moderate ulcerative colitis
Tests acupuncture alongside mesalazine in adults with active ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis.
Key facts
- Where
- Wuhan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07389824, who can take part
Where in China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qin Yu
- Trial code
- NCT07389824
- Record updated
- 25 August 2026
- Original description
This study aims to evaluate the efficacy and safety of acupuncture combined with mesalazine (an integrated acupuncture-medication regimen) for ulcerative colitis.Read full original descriptionShow less
Efficacy of Acupuncture Combined With Mesalazine in Inducing and Maintaining Clinical Remission in Mild-to-Moderate Active Ulcerative Colitis: A Single-Center, Randomized Controlled Clinical Trial.
This study aims to evaluate the efficacy and safety of acupuncture combined with mesalazine (an integrated acupuncture-medication regimen) for ulcerative colitis.
Inclusion: documented diagnosis of UC；; age 18-75 years, regardless of gender; mildly to moderately active UC, defined as a baseline total Mayo score between 3 and 10；; willing to receive the complete protocol of intradermal thumbtack needle embedding therapy (12 sessions across three treatment courses)；; Willing to undergo two colonoscopies (pre-treatment and post-treatment)；; complete all baseline assessments; capable of understanding and voluntarily sign the informed consent form.
Exclusion: diagnosed with or suspected to have other type of inflammatory bowel disease, such as Crohn's disease; patients in clinical remission or with severe disease activity ( baseline total Mayo score < 3, or > 10 ); having severe gastrointestinal complications or a recent surgical history, including but not limited to: short bowel syndrome, toxic megacolon, intestinal perforation, complete intestinal obstruction, active massive gastrointestinal hemorrhage, or having undergone major abdominal or intestinal surgery within the past 6 months; significant or unstable comorbidities (e.g., cardiovascular, respiratory, hepatic, or renal diseases); patients with malignant tumors (including but not limited to colorectal cancer); patients with a history of intradermal thumbtack needle embedding; patients with mental illness; patients with either coagulation disorders or skin conditions (such as diseases, infections, ulcers, scars, or tumors at the acupuncture sites) that would preclude acupuncture；; any other condition (e.g., geographical remoteness, history of poor adherence) that, in the opinion of the investigator, would make the patient unsuitable for the study or likely to be non-compliant with the protocol; patients unwilling to undergo colonoscopy; pregnant or lactating women; strong needle phobia or unwillingness to receive acupuncture treatment.